DrugPatentWatch Database Preview
Details for Biologics License Application: 125293
» See Plans and Pricing
Summary for BLA: 125293
| Tradename: | KRYSTEXXA |
| Applicant: | Horizon Pharma |
| Ingredient: | pegloticase |
| Patents: | 1 |
| Approval Date: | Oct 19, 2010 |
Pharmacology for BLA: 125293
| Ingredient-type | Urate Oxidase |
| Drug Class | Uric Acid-specific Enzyme |
US Patents for BLA: 125293
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Horizon Pharma | KRYSTEXXA | pegloticase | INJECTABLE; INJECTION | 125293 | 001 | 2010-10-19 | Start Trial | Selecta Biosciences, Inc. (Watertown, MA) | 2033-05-03 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
